217 related articles for article (PubMed ID: 10667469)
1. A case-control study of galactose consumption and metabolism in relation to ovarian cancer.
Cramer DW; Greenberg ER; Titus-Ernstoff L; Liberman RF; Welch WR; Li E; Ng WG
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):95-101. PubMed ID: 10667469
[TBL] [Abstract][Full Text] [Related]
2. The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer.
Fung WL; Risch H; McLaughlin J; Rosen B; Cole D; Vesprini D; Narod SA
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):678-80. PubMed ID: 12869412
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of women with a family history of ovarian cancer. I. Galactose consumption and metabolism.
Cramer DW; Muto MG; Reichardt JK; Xu H; Welch WR; Valles B; Ng WG
Cancer; 1994 Aug; 74(4):1309-17. PubMed ID: 8055453
[TBL] [Abstract][Full Text] [Related]
4. Lactose and galactose intake and metabolism in relation to the risk of epithelial ovarian cancer.
Herrinton LJ; Weiss NS; Beresford SA; Stanford JL; Wolfla DM; Feng Z; Scott CR
Am J Epidemiol; 1995 Mar; 141(5):407-16. PubMed ID: 7879785
[TBL] [Abstract][Full Text] [Related]
5. Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, and the risk of borderline and invasive ovarian cancer (United States).
Cozen W; Peters R; Reichardt JK; Ng W; Felix JC; Wan P; Pike MC
Cancer Causes Control; 2002 Mar; 13(2):113-20. PubMed ID: 11936817
[TBL] [Abstract][Full Text] [Related]
6. Galactose consumption and metabolism in relation to the risk of ovarian cancer.
Cramer DW; Harlow BL; Willett WC; Welch WR; Bell DA; Scully RE; Ng WG; Knapp RC
Lancet; 1989 Jul; 2(8654):66-71. PubMed ID: 2567871
[TBL] [Abstract][Full Text] [Related]
7. Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies.
Genkinger JM; Hunter DJ; Spiegelman D; Anderson KE; Arslan A; Beeson WL; Buring JE; Fraser GE; Freudenheim JL; Goldbohm RA; Hankinson SE; Jacobs DR; Koushik A; Lacey JV; Larsson SC; Leitzmann M; McCullough ML; Miller AB; Rodriguez C; Rohan TE; Schouten LJ; Shore R; Smit E; Wolk A; Zhang SM; Smith-Warner SA
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):364-72. PubMed ID: 16492930
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
[TBL] [Abstract][Full Text] [Related]
9. Positive correlation between galactose-1-phosphate uridyltransferase (GALT) and UDP-galactose-4'-epimerase (GALE) activities.
Prodan-Zitnik I; Karas-Kuzelicki N; Lukac-Bajalo J
Clin Biochem; 2009 Oct; 42(15):1561-4. PubMed ID: 19616531
[TBL] [Abstract][Full Text] [Related]
10. Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer.
Goodman MT; Wu AH; Tung KH; McDuffie K; Cramer DW; Wilkens LR; Terada K; Reichardt JK; Ng WG
Am J Epidemiol; 2002 Oct; 156(8):693-701. PubMed ID: 12370157
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy and risk of epithelial ovarian cancer.
Purdie DM; Bain CJ; Siskind V; Russell P; Hacker NF; Ward BG; Quinn MA; Green AC
Br J Cancer; 1999 Oct; 81(3):559-63. PubMed ID: 10507786
[TBL] [Abstract][Full Text] [Related]
12. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
Berchuck A; Schildkraut JM; Wenham RM; Calingaert B; Ali S; Henriott A; Halabi S; Rodriguez GC; Gertig D; Purdie DM; Kelemen L; Spurdle AB; Marks J; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2141-7. PubMed ID: 15598772
[TBL] [Abstract][Full Text] [Related]
13. Psychotropic medication use and risk of epithelial ovarian cancer.
Harlow BL; Cramer DW; Baron JA; Titus-Ernstoff L; Greenberg ER
Cancer Epidemiol Biomarkers Prev; 1998 Aug; 7(8):697-702. PubMed ID: 9718222
[TBL] [Abstract][Full Text] [Related]
14. Use of dairy products, lactose, and calcium and risk of ovarian cancer - results from a Danish case-control study.
Faber MT; Jensen A; Søgaard M; Høgdall E; Høgdall C; Blaakaer J; Kjaer SK
Acta Oncol; 2012 Apr; 51(4):454-64. PubMed ID: 22397392
[TBL] [Abstract][Full Text] [Related]
15. The occurrence of the Leloir pathway in non-pathogenic mycobacteria.
Szumiło T
Acta Microbiol Pol; 1981; 30(4):327-33. PubMed ID: 6179392
[TBL] [Abstract][Full Text] [Related]
16. Differential roles of the Leloir pathway enzymes and metabolites in defining galactose sensitivity in yeast.
Ross KL; Davis CN; Fridovich-Keil JL
Mol Genet Metab; 2004; 83(1-2):103-16. PubMed ID: 15464425
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of human UDP-glucose pyrophosphorylase rescues galactose-1-phosphate uridyltransferase-deficient yeast.
Lai K; Elsas LJ
Biochem Biophys Res Commun; 2000 May; 271(2):392-400. PubMed ID: 10799308
[TBL] [Abstract][Full Text] [Related]
18. Milk consumption, galactose metabolism and ovarian cancer (Australia).
Webb PM; Bain CJ; Purdie DM; Harvey PW; Green A
Cancer Causes Control; 1998 Dec; 9(6):637-44. PubMed ID: 10189050
[TBL] [Abstract][Full Text] [Related]
19. Lactase persistence, dietary intake of milk, and the risk for prostate cancer in Sweden and Finland.
Torniainen S; Hedelin M; Autio V; Rasinperä H; Bälter KA; Klint A; Bellocco R; Wiklund F; Stattin P; Ikonen T; Tammela TL; Schleutker J; Grönberg H; Järvelä I
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):956-61. PubMed ID: 17507622
[TBL] [Abstract][Full Text] [Related]
20. The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Spurdle AB; Hopper JL; Chen X; Dite GS; McCredie MR; Giles GG; Venter DJ; Southey MC; Purdie DM; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1287-93. PubMed ID: 11751447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
